Relmada Therapeutics Inc (OTCMKTS:RLMD) Director Paul Edward Kelly purchased 150,000 shares of Relmada Therapeutics stock in a transaction dated Friday, October 12th. The stock was acquired at an average price of $0.90 per share, for a total transaction of $135,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of Relmada Therapeutics stock remained flat at $$1.16 during trading on Monday. The stock had a trading volume of 5,120 shares, compared to its average volume of 14,019. Relmada Therapeutics Inc has a 52-week low of $0.61 and a 52-week high of $1.94.
Separately, ValuEngine upgraded Relmada Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday.
Relmada Therapeutics Company Profile
Relmada Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases, primarily depression and chronic pain in the United States. Its lead product candidate, d-Methadone, is being developed as a rapidly acting, oral agent for the treatment of depression, neuropathic pain, and/or other potential CNS pathological conditions.
See Also: What are the Benefits of Index Funds?